Medical Imaging: approx. 60%
Radiation Therapy: approx. 25%
Artificial Intelligence and Software Solutions: approx. 15%

TOP 3 Markets:

China: approx. 50%
USA: approx. 20%
Europe: approx. 15%

Shanghai United Imaging Healthcare Co., Ltd. generates the majority of its revenue from medical imaging, followed by radiation therapy and software solutions based on artificial intelligence. The domestic market of China is the largest revenue contributor, followed by the USA and Europe, which also have significant shares of the total revenue.

The company benefits from strong demand for advanced medical technologies in these regions and continuously invests in research and development to strengthen its market position.

Production Sites: Shanghai, China

Shanghai United Imaging Healthcare Co., Ltd. mainly produces its products in Shanghai, China. The company has modern production facilities there that specialize in the manufacturing of medical imaging devices. This strategic location enables the company to efficiently serve both the domestic market and international markets.

Focus on Research and Development: 15% of revenue (2024)

International Expansion: 20 new markets by 2026

Partnerships and Collaborations: Collaboration with leading healthcare institutions

Shanghai United Imaging Healthcare Co., Ltd. pursues a strategy that is heavily focused on research and development (R&D). The company invests approximately 15% of its revenue in R&D to develop innovative medical devices and technologies. These investments are intended to enhance competitiveness in the global market.

Another key focus is on international expansion. The company plans to enter 20 new markets by 2026. This strategy aims to increase global presence and tap into new revenue sources.

Additionally, the company is leveraging strategic partnerships and collaborations with leading healthcare institutions worldwide. These alliances are designed to facilitate access to new technologies and markets, further strengthening the company's innovation capabilities.

Main raw materials: Rare earths, semiconductors, metals

Countries of origin: USA, Japan, South Korea, Australia

Shanghai United Imaging Healthcare Co., Ltd. is a leading company in the field of medical imaging and diagnostic technology. The company requires a variety of raw materials and materials for the production of its advanced devices. These include rare earths and semiconductors, which are essential for the production of high-tech components.

Rare earths are mainly imported from countries such as the USA and Australia, which have significant reserves and production capacities. The company sources semiconductors and specialized electronic components mainly from Japan and South Korea, known for their advanced technology and high quality standards.

These international supply chains are crucial to ensure the quality and performance of products from Shanghai United Imaging Healthcare.

Market Share in China: 20% (2024, estimated)
R&D Expenditure: 12% of revenue (2024)
International Expansion: 10 new markets (2023)

Shanghai United Imaging Healthcare Co., Ltd. has established itself as one of the leading providers in the field of medical imaging in China. With an estimated market share of 20% in 2024, the company demonstrates a strong presence in its domestic market.

A key competitive advantage of the company lies in its high investments in research and development, accounting for approximately 12% of revenue. These investments enable the company to continuously develop innovative products and differentiate itself technologically from the competition.

Furthermore, Shanghai United Imaging Healthcare has expanded its international presence by entering 10 new markets in 2023. This expansion not only enhances global brand awareness but also diversifies the company's revenue sources, contributing to a more robust market position.

Overall, the company positions itself as a strong competitor in the global medical technology industry through its innovation capabilities and international expansion.

Institutional Investor Share: 45% (estimated for 2025 based on trends and market analysis)

Insider Buys/Sells: No significant changes reported (2025)

The institutional investor share in Shanghai United Imaging Healthcare Co., Ltd. is estimated to be around 45%. This estimate is based on the observation of trends in the industry and the typical involvement of institutional investors in comparable companies.

Regarding insider buys and sells, there have been no significant changes or transactions reported for the year 2025. This suggests that the management and other insiders are currently not making any significant adjustments to their holdings.

Market share of Shanghai United Imaging Healthcare Co., Ltd.: 12% (estimated for 2025)

Top competitors and their market shares:

1. Siemens Healthineers - 20%
2. GE Healthcare - 18%
3. Philips Healthcare - 15%
4. Shanghai United Imaging Healthcare Co., Ltd. - 12%
5. Canon Medical Systems - 10%
6. Hitachi Medical Systems - 8%
7. Fujifilm Holdings Corporation - 7%
8. Hologic, Inc. - 5%
9. Mindray Medical International - 3%
10. Varian Medical Systems - 2%

Shanghai United Imaging Healthcare Co., Ltd. has established itself as a significant player in the field of medical imaging in recent years. The market share of 12% indicates that the company holds a strong position in the market, although it lags behind major international players such as Siemens Healthineers and GE Healthcare.

The moat of Shanghai United Imaging Healthcare lies in its strong focus on the Asian market, particularly China, where it benefits from local expertise and a quick adaptability to regulatory requirements. This provides an advantage over international competitors who may face longer market entry times and higher costs.

However, compared to other companies, Siemens Healthineers and GE Healthcare have deeper moats supported by their global presence, extensive product portfolios, and strong brand recognition. These factors make it challenging for Shanghai United Imaging Healthcare to significantly penetrate other international markets.

In summary, Shanghai United Imaging Healthcare has a solid regional moat, but international competitors have the upper hand in terms of global reach and brand strength.

Revenue Growth: 20% (2024)
Research and Development Ratio: 15% of revenue (2024)
Market Share in China: 25% (2024)

Shanghai United Imaging Healthcare Co., Ltd. achieved an impressive revenue growth of 20% in 2024. This indicates strong demand for their products and services, especially in the field of medical imaging.

The company continues to invest heavily in research and development, accounting for 15% of revenue. These investments are crucial for developing new technologies and maintaining competitiveness in a fast-paced market.

With a market share of 25% in China, Shanghai United Imaging Healthcare is a significant player in the industry. This position provides a solid foundation for further growth, especially given the increasing demand for advanced medical solutions in the region.

Overall, the company demonstrates strong fundamental metrics and a strategic focus on innovation, making it a potentially attractive investment.

Dividend payment: No dividend (2025)

Shanghai United Imaging Healthcare Co., Ltd. has not paid any dividends so far. The company is heavily focused on growth and reinvesting in research and development to strengthen its market position in the field of medical imaging and healthcare solutions.

As the company operates in a highly innovation-driven industry, it is common for profits to be invested in advancing technologies and expansion rather than distributed as dividends. This could change in the future if the company achieves its growth targets and establishes a more stable financial foundation.